icon- folder.gif   Conference Reports for NATAP  
 
  IAS
25th International AIDS Conference
22 to 26 July 2024
 Back grey_arrow_rt.gif
 
 
 
New HIV Drug Development at IAS 2024
 
 
  Twice-Yearly Lenacapavir or Daily Emtricitabine/Tenofovir Alafenamide for HIV Prevention in Cisgender Women: Interim Analysis Results from the PURPOSE 1 Study - (07/28/24)
 
Phase 1, open-label study to evaluate the drug interaction between MK-8527, an HIV-1 nucleoside reverse transcriptase translocation inhibitor, and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females - (08/06/24)
 
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024 - (07/31/24)
 
Preclinical Assessments of a Cabotegravir Prodrug Predicting Human Dosing Durations of >6 Months - (07/30/24)
 
Phase 1 study of VH4524184 (VH-184), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile - (07/29/24)
 
In vitro characterization of VH4524184 (VH-184, S-365598), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile - (07/29/24)
 
Third-Generation Integrase Inhibitor Remains Active Against Resistant HIV in Lab - (07/27/24)
 
ViiV HEALTHCARE PREMIERES EARLY DATA SHOWING ANTIVIRAL ACTIVITY AGAINST INTEGRASE RESISTANCE FROM ITS INVESTIGATIONAL, THIRD-GENERATION INTEGRASE INHIBITOR - (07/30/24)
 
Pre-Clinical Profiles of HIV-1 Capsid Inhibitors VH4004280 (VH-280) and VH4011499 (VH-499) - (07/30/24)
 
Clinical Pharmacokinetics and Safety of Orally Administered VH4004280 (VH-280), a Novel HIV-1 Capsid Inhibitor, in Adults Without HIV - (07/29/24)
 
GS-8588, A Novel Envelope-Targeting Bispecific T-Cell Engager for HIV Cure - (07/30/24)
 
Nonclinical Pharmacology Profile of GS-1720, a Novel, Highly Potent, Once-Weekly Oral HIV-1 Integrase Strand Transfer Inhibitor in Clinical Development - (07/29/24)
 
Safety and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GS-4182, an Oral Prodrug of Lenacapavir, in Participants without HIV-1 - (07/29/24)